Kala Pharmaceuticals, Inc.
KALA
We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome ( MSC-S ) platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly …
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$10M
▲ +29.9% YoY
Op. Margin
–
ROIC
-79.24%
▼ -46.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$20M
▼ -8.9% YoY
Op. Cash Flow (TTM)
-$20M
▼ -8.9% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with KALA
Kala Pharmaceuticals (KALA) in three numbers
Questions about Kala Pharmaceuticals
Is Kala Pharmaceuticals a high-quality business?
Kala Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$7M, and its weakest is return on capital at -79.2%. The Quality tab shows every check against its target.
Does Kala Pharmaceuticals (KALA) pay a dividend?
No. Kala Pharmaceuticals (KALA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 19 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in KALA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KALA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.